Nuvectis Pharma, Inc. - Common Stock (NQ:NVCT)

21.92 +1.20 (+5.79%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Nuvectis Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Insiders Buying Steel Connect And 2 Other Stocks ↗

July 21, 2023

Although US stocks closed mixed on Thursday, there were a few notable insider trades.

Via Benzinga

Insiders Buying Nuvectis Pharma And 2 Other Stocks ↗

July 20, 2023

Although US stocks closed mostly higher on Wednesday, there were a few notable insider trades.

Via Benzinga

Insiders Buying Joint Corp And 2 Other Stocks ↗

July 19, 2023

Although US stocks closed higher on Tuesday, there were a few notable insider trades.

Via Benzinga

Insiders Buying BranchOut Food And 2 Other Stocks ↗

July 14, 2023

Although US stocks closed higher for the fourth session in a row, there were a few notable insider trades.

Via Benzinga

Insiders Buying Asana And 2 Other Stocks ↗

July 13, 2023

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock....

Via Benzinga

More Than $3M Bet On Asana? Check Out These 3 Stocks Insiders Are Buying ↗

July 11, 2023

Although US stocks closed higher on Monday, there were a few notable insider trades.

Via Benzinga

Nuvectis Pharma: Q1 Earnings Insights ↗

May 10, 2023

Via Benzinga

$1M Bet On Children's Place? Check Out These 3 Stocks Insiders Are Buying ↗

July 07, 2023

Although US stocks closed lower on Thursday, there were a few notable insider trades.

Via Benzinga

Nuvectis Pharma Set to Join the Russell 2000® and Russell 3000® Indexes

June 20, 2023

From Nuvectis Pharma, Inc.

Via GlobeNewswire

Over $2M Bet On This Financial Services Stock? Check Out These 3 Stocks Insiders Are Buying ↗

June 20, 2023

Although US stocks closed lower on Friday, there were a few notable insider trades.

Via Benzinga

Nuvectis Pharma Announces FDA Clearance of NXP900 IND

May 15, 2023

From Nuvectis Pharma, Inc.

Via GlobeNewswire

Correction: Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

April 27, 2023

From Nuvectis Pharma, Inc.

Via GlobeNewswire

Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

April 27, 2023

From Nuvectis Pharma, Inc.

Via GlobeNewswire

Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800's Activity in Cholangiocarcinoma PDX Models at the 2023 American Association for Cancer Research (“AACR”) Annual Meeting

April 18, 2023

From Nuvectis Pharma, Inc.

Via GlobeNewswire

Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian Carcinoma

April 10, 2023

Phase 1b study builds on highly consistent preclinical and Phase 1a data

From Nuvectis Pharma, Inc.

Via GlobeNewswire

Nuvectis Pharma Announces Upcoming Presentations at the 2023 American Association for Cancer Research Meeting

March 17, 2023

From Nuvectis Pharma, Inc.

Via GlobeNewswire

Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference

March 10, 2023

From Nuvectis Pharma, Inc.

Via GlobeNewswire

Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800 at the 2023 ESMO Gynecological Cancers Congress

February 23, 2023

Treatment with NXP800 resulted in substantial tumor growth inhibition in two in vivo xenograft models of ARID1a-mutated ovarian carcinoma, superior to treatment with cisplatin

From Nuvectis Pharma, Inc.

Via GlobeNewswire

Nuvectis Pharma Announces Collaboration with ENGOT and GOG Foundation to Conduct the NXP800 Phase 1b Clinical Trial in ARID1A-Mutated Ovarian Carcinoma in Europe and in the United States

January 04, 2023

From Nuvectis Pharma, Inc.

Via GlobeNewswire

FDA Grants Fast Track Designation to Nuvectis Pharma's NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma

December 01, 2022

From Nuvectis Pharma, Inc.

Via GlobeNewswire

Nuvectis Pharma, Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference

October 03, 2022

From Nuvectis Pharma, Inc.

Via GlobeNewswire

Nuvectis Pharma Announces Formation of a Scientific Advisory Board

September 28, 2022

From Nuvectis Pharma, Inc.

Via GlobeNewswire

Nuvectis Pharma, Inc. Announces Approximately $15.9 Million Private Placement

July 27, 2022

From Nuvectis Pharma, Inc.

Via GlobeNewswire

Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday ↗

July 27, 2022

Gainers Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) shares surged 94.3% to close at $1.69 on Tuesday after the company filed a request for the withdrawal of the Registration Statement on Form S-1.

Via Benzinga

5 Best Performing Micro-Cap Stocks Through the First Half of 2022

July 05, 2022

The first half of 2022 is finally in the books and it could not have come sooner. Major U.S. indices

Via Spotlight Growth

Topics Stocks

Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2022 ↗

July 13, 2022

Upgrades

Via Benzinga

Recap of Tuesday's Biotech Catalysts - End of the Day Summary ↗

June 21, 2022

Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid...

Via Benzinga

Nuvectis Pharma Gets FDA Nod For Initial-Stage Ovarian Cancer Study ↗

June 21, 2022

The U.S. Food and Drug Administration (FDA) cleared Nuvectis Pharma’s (NASDAQ: NVCT) Investigational New Drug Application (IND) for NXP800, which includes the Phase 1 clinical trial protocol.

Via Benzinga

82 Biggest Movers From Yesterday ↗

June 15, 2022

Gainers Comera Life Sciences Holdings, Inc. (NASDAQ: CMRA) gained 126.5% to settle at $2.65 on Tuesday.

Via Benzinga

92 Biggest Movers From Friday ↗

May 09, 2022

Gainers Sidus Space, Inc. (NASDAQ: SIDU) jumped 51.8% to settle at $2.99 on Friday after the company announced a a memorandum of understanding with Dhruva Space to expand its partnership to further the...

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.